BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC lobbying for BOEHRINGER INGELHEIM USA CORPORATION

Filing 1st Quarter - Report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 20, 2026

Expenses

$1,165,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 1

WILLIAM DENT Former member of Congress New on this filing

Previously held: Director, Federal Government Affairs. Sen. Marshall, Rep. John Joyce, Sen. Tillis, Rep. Buddy Carter

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 5

Agriculture, Dept of (USDA)
Centers For Medicare and Medicaid Services (CMS)
Environmental Protection Agency (EPA)
HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 8

HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
S 832
EPIC Act of 2025
HR 946
ORPHAN Cures Act
S 1862
ORPHAN Cures Act
HR 842
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
S 339
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
HR 1842
PAW Act of 2025
HR 8467
Farm, Food, and National Security Act of 2024

Lobbying activity 4

Health Issues

Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax and tariffs Issues related to Intellectual Property Issues related to Inflation Reduction Act

Medicare/Medicaid

Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act

Animals

Issues related to Animal Health Issues related to One Health Issues Related to PAW Act (H.R. 1842) Far, Food and National Security Act of 2024 (H.R. 8467) Issues related to the regulatory process Issues related to transboundary animal disease control and prevention Issues related to avian influenza Issues related to New World Screwworm Issues Related to Tax and Trade

Budget/Appropriations

Issues related to FY2026 Appropriations